TopoTarget A/S
Symbion
Fruebjergvej 3
DK 2100 Copenhagen
Denmark
Tel: +45 39 17 83 92
Fax: +45 39 17 94 92
CVR-nr: 25695771
www.topotarget.com
Report pursuant to the Danish Securities Trading Act, Section 28a
Copenhagen - 6 December 2007 - Pursuant to the Danish Securities Trading Act,
Section 28a TopoTarget A/S (OMX: TOPO) is obliged to report on transactions by
members of its senior management and their related parties in shares issued by
TopoTarget A/S and related securities.
Name Leif Hamø
Reason CFO
Issuer and ISIN code TopoTarget A/S, DK0060086072
Transaction Purchase
Trade date 27 November 2007
Market Copenhagen Stock Exchange
Number 10,000
Market value in DKK 209,000
TopoTarget A/S
For further information, please contact:
Dr. Peter Buhl Jensen Telephone +45 39 17 83 41
Chief Executive Officer Mobile +45 21 60 89 22
Background information
About TopoTarget
TopoTarget (OMX: TOPO) is a biotech company, headquartered in Denmark and with
subsidiaries in the UK, Germany, Switzerland and the US, dedicated to finding
''Answers for Cancer'' and developing improved cancer therapies. TopoTarget is
founded and run by clinical cancer specialists and combines years of hands-on
clinical experience with in-depth understanding of the molecular mechanisms of
cancer. Focus lies on highly predictive cancer models and key cancer targets
(including HDACi, NAD+, mTOR, FASligand and topoisomerase II inhibitors) and a
strong development foundation has been built. TopoTarget has a broad portfolio
of small molecule pre-clinical drug candidates and eight drugs (both small
molecules and protein based) are in clinical development, including both novel
anti-cancer therapeutics and new cancer indications for existing drugs.
Savene™/Totect™ is TopoTarget's first product on the market. For more
information, please refer to www.topotarget.com.
